GNTbm focuses on the R&D of oral new drugs in cancer immunotherapy, including tumor microenvironment regulators (TMRs), epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors.

Anbogen’s drug pipeline features two lead small‑molecule candidates: “ABT‑101,” a tyrosine kinase inhibitor targeting HER2 exon20 insertion mutations in non‑small cell lung cancer; and “ABT‑301,” an HDAC1/2/3 inhibitor designed for combination therapy wit